Generic Name and Formulations:
Timolol maleate 0.25%, 0.5%; oph gel forming soln.
Valeant Pharmaceuticals, Inc
Indications for TIMOPTIC-XE:
Elevated intraocular pressure in ocular hypertension or open-angle glaucoma.
Adults and Children:
<2yrs: not established. Invert closed bottle and shake once before each use. ≥2yrs: 1 drop once daily. Give other oph. drugs at least 10 minutes before.
Greater than 1st-degree AV block. Uncompensated cardiac failure. Cardiogenic shock. Sinus bradycardia. History of bronchospasm. Bronchial asthma. Severe COPD.
Not for use as sole agent in angle-closure glaucoma. Poor cardiac reserve should be controlled with digitalis and diuretics. Diabetes. Presbyopia. May mask hypoglycemia or thyrotoxicosis. Myasthenia gravis. Cerebrovascular insufficiency. Measure intraocular pressure after 4 weeks of treatment. Avoid abrupt cessation. Discontinue at 1st sign of cardiac failure and before surgery. Pregnancy. Nursing mothers: not recommended.
May potentiate systemic β-blockers, reserpine, hypoglycemics and mydriatic effect of topical epinephrine. Additive cardiac and pulmonary effects with anticholinesterase miotics. May antagonize bronchodilation from β-adrenergic agonists. May cause conduction defects with calcium channel blockers, digoxin. May be potentiated by CYP2D6 inhibitors (eg, quinidine, SSRIs).
Ocular irritation, sensitization, rash, dizziness, blurred vision, corneal anesthesia, headache, GI upset, paresthesias. Systemic β-blocker effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). Aphakic maculopathy (rare).
Soln—contact supplier; Ocudose—60; XE—2.5mL, 5mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer